Intensity Therapeutics (INTS) Interest Expenses (2022 - 2026)
Intensity Therapeutics' (INTS) quarterly Interest Expenses came in at $113000.0 in Q1 2026, up 564.71% YoY from $17000.0 in Q1 2025, and up 527.78% on a QoQ basis from $18000.0 in Q4 2025.
Intensity Therapeutics (INTS) Interest Expenses (2022 - 2026) Analysis & Trends
Intensity Therapeutics (INTS) has 5 years of Interest Expenses data on file, last reported at $113000.0 in Q1 2026.
- Quarterly Interest Expenses rose 564.71% year-over-year to $113000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $113000.0 (up 117.31% YoY) and the FY2025 annual result came in at $68000.0, down 99.58% from the prior year.
- Interest Expenses advanced to $113000.0 in Q1 2026, from $18000.0 in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $492000.0 in Q2 2023 to a low of -$1000.0 in Q4 2024.
- A 5-year average of $72213.7 and a median of $19000.0 in 2024 frame the typical range for Interest Expenses.
- Annual changes were most pronounced in 2023 — Interest Expenses surged 3188.99% — and 2024, when it slumped 96.39%.
- Tracing INTS's Interest Expenses over 5 years: stood at $37123.0 in 2022, then surged by 128.97% to $85000.0 in 2023, then sank by 101.18% to -$1000.0 in 2024, then jumped by 1900.0% to $18000.0 in 2025, then jumped by 527.78% to $113000.0 in 2026.
- The last three Interest Expenses figures came in at $113000.0 (Q1 2026), $18000.0 (Q4 2025), and $131000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 82.05 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 20.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 93.62 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -4.89 Mn |
| 10 | Intensity Therapeutics | 13.06 Mn | 13.06 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 104,000.00 |
| Jun 30, 2026 | 104,000.00 |
| Mar 31, 2026 | 113,000.00 |
| Mar 31, 2026 | 113,000.00 |
| Dec 31, 2025 | 18,000.00 |
| Dec 31, 2025 | 18,000.00 |
| Sep 30, 2025 | 131,000.00 |
| Sep 30, 2025 | 131,000.00 |
| Jun 30, 2025 | 39,000.00 |
| Jun 30, 2025 | 39,000.00 |
| Mar 31, 2025 | 17,000.00 |
| Mar 31, 2025 | 17,000.00 |
| Dec 31, 2024 | -1,000.00 |
| Dec 31, 2024 | -1,000.00 |
| Sep 30, 2024 | 17,000.00 |
| Sep 30, 2024 | 17,000.00 |
| Jun 30, 2024 | 19,000.00 |
| Jun 30, 2024 | 19,000.00 |
| Mar 31, 2024 | 3,000.00 |
| Mar 31, 2024 | 3,000.00 |